3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
16
Carcinoma, Hepatocellular
11
Stomach Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myositis
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Vascular Complications
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Sarcopenia
1
Recurrence
1
Rectal Neoplasms
1
Plaque, Atherosclerotic
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metastatic Colorectal Adenocarcinoma
1
Melanoma
1
Lupus Erythematosus, Systemic
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Influenza, Human
1
Immune-Related Adverse Events
1
Hypersensitivity
1
Interventions
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
Ultrasonography
1
Lutetium-177
1
Lutetium
1
Immune Checkpoint Inhibitors
1
Hematologic Tests
1
Eating
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Endocrine System Diseases
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03492242
2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed
1,000 enrolled